National Center for Emerging and Zoonotic Infectious Diseases



Antimicrobial Resistance (AR) Option Benchmark Metrics: Standardized Resistant Infection Ratio (SRIR) & Pathogen-specific Standardized Infection Ratio (pSIR)

Erin O'Leary, MPH
Senior Data Analyst
Lantana Consulting Group

NHSN Annual Training March 2023

Objectives

- Provide an overview of new AR Option benchmark metrics
- Describe methods used to develop SRIRs and pSIRs
- Describe statistical model details
- Interpret forthcoming SRIR and pSIR reports in NHSN

Overview of SRIRs and pSIRs

Overview

- We developed two new AR benchmark metrics in 2021/2022 using 2019 as the baseline year
 - SRIR: Standardized Resistant Infection Ratio
 - pSIR: pathogen-specific Standardized Infection Ratio
- Both are observed-to-predicted ratios (like SAARs, SIRs, SURs)

SRIR Overview

 SRIRs allow facilities to compare their number of observed hospitalonset* (HO) resistant infections for eligible phenotypes, to the number predicted, based on 2019 baseline risk-adjusted AR models

$$SRIR = \frac{Observed\ Resistant\ Infections}{Predicted\ Resistant\ Infections}$$

*Hospital-onset is defined as a specimen collected in an inpatient location on or after day 4 (where day 1 is date of admission)

Target SRIR Antimicrobial Resistant Phenotypes

- Observed resistant infections are the number of resistant HO isolates reported to NHSN for the following phenotypes*:
 - Carbapenem-resistant Enterobacterales
 - Extended-spectrum cephalosporinresistant Enterobacterales
 - Fluoroquinolone-resistant
 Enterobacterales

- Vancomycin-resistant Enterococcus
- Fluoroquinolone-resistant P. aeruginosa
- Multi-drug-resistant P. aeruginosa
- Methicillin-resistant S. aureus
- Predicted resistant infections are the number of resistant HO isolates for a particular phenotype, predicted for a hospital based on negative binomial regression modeling applied to nationally aggregated 2019 AR data

^{*}Phenotype definitions can be found in the AUR Module Protocol: https://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf

Criteria for Generating SRIRs

- Facility-wide SRIRs can be calculated for three specimen sources:
 - Blood
 - Urine
 - Lower respiratory tract (LRT)
- For a facility to calculate a SRIR, they must have reported:
 - At least one HO isolate for the eligible organism from the correct specimen source during the specified time period of interest
 - Example SRIR for 2022 Q3 Vancomycin-resistant Enterococcus in blood: the facility must report at least one HO Enterococcus from blood in month 7, 8, or 9 of 2022

pSIR Overview

 pSIRs allow facilities to compare their number of observed HO infections for eligible organisms, to the number predicted, based on 2019 baseline risk-adjusted AR models

$$pSIR = \frac{Observed\ Infections}{Predicted\ Infections}$$

Target pSIR Organisms

- Observed infections are the number of HO isolates reported to NHSN for the following four eligible pathogens/pathogen groups:
 - Enterobacterales
 - Enterococcus
 - Pseudomonas aeruginosa
 - Staphylococcus aureus
- Predicted infections are the number of HO isolates for a particular pathogen/pathogen group, predicted for a hospital based on negative binomial regression modeling applied to nationally aggregated 2019 AR data

Criteria for Generating pSIRs

- Facility-wide pSIRs can be calculated for three specimen sources:
 - Blood
 - Urine
 - Lower respiratory tract
- For a facility to calculate a pSIR, they must have reported:
 - At least one HO isolate (any organism) from the correct specimen source during the specified time period of interest
 - Example pSIR 2022 Q3 Enterococcus in blood: the facility must report at least one HO isolate from blood in month 7, 8, or 9 of 2022

Why were these metrics developed?

- SRIRs and pSIRs enable hospitals to compare their rates of resistant HO infections and HO infections to a national average
- Using incidence and prevalence instead of % susceptible for benchmarking minimizes the bias of selective/cascade antimicrobial susceptibility testing/reporting* in some hospitals
 - *https://doi.org/10.1128/spectrum.01646-22

How were phenotypes/organisms selected?

- Selected by a group of internal subject matter experts
- Target phenotypes were relatively common AR threats that could spread widely in hospital settings
 - Of interest to hospital infection prevention and antimicrobial stewardship programs
 - Benchmarking metrics for selected phenotypes can enable inter-facility comparisons
 - Rare AR phenotypes were not prioritized for benchmarking but worth investigating if seen in other NHSN reports

Methods used to develop SRIRs and pSIRs

Methods

- Data Sources:
 - 2019 AR Option data (reported as of August 2021)
 - 2019 Patient Safety Component Annual Survey data
- Level of aggregation for model development:
 - Facility-year

Exclusion criteria

- Exclusions:
 - Facilities reporting <9 months of AR data in 2019
 - Facilities missing patient days
 - Facilities reporting admissions=0*
 - For each specimen source type, facilities missing antimicrobial susceptibility results for >10% of HO isolates for the organism in question*
 - Records where susceptibility results were missing*

*SRIR models only

Facility-level factors assessed for risk adjustment

- Facility type
- Number of beds
- Number of ICU beds.
- Percentage of ICU beds
- Medical school affiliation
- Medical school affiliation type (i.e., undergrad, grad, major teaching)
- Hospital length of stay (annual # patient days / annual # admissions)
- Community-onset (CO) prevalence* (# resistant CO isolates / 10,000 admissions)

Source: NHSN Annual Hospital Survey; except CO prevalence which is calculated from AR Option data

^{*}Only assessed in SRIR models

Statistical modeling

- We used negative binomial regression to assess associations between rates of resistant HO infections and potential risk-factors (SRIR models) and rates of HO infections and potential risk-factors (pSIR models)
- Models were created for each phenotype (SRIR models) or pathogen/group of pathogens (pSIR models) for each specimen source (blood, lower respiratory tract, urine)
- This resulted in development of 21 SRIR models and 12 pSIR models
 - SRIRs: 7 phenotypes * 3 specimen sources = 21 models
 - pSIRs: 4 pathogens/pathogen groups * 3 specimen sources = 12 models

Referent population

- The number of hospitals included in each analytic dataset differs depending on which phenotype or pathogen the hospital reports from each specimen source type
- Facility types represented in 2019 AR data include: critical access, children's, general acute care, long-term acute care, oncology, psychiatric, inpatient rehabilitation, surgical, women's, and women's and children's hospitals
- Not all of these facility types are represented in the referent population for all models

Isolate summary for SRIR models

Pathogen	Drug-resistance	Specimen source	Number of facilities in analytic dataset	Number of drug resistant isolates	Number of tested isolates	Total patient- days	Pooled resistant isolate rate, per 1000 patient-days	Resistant isolate rate per 1000 patient-days, Median (Q1, Q3)
Enterobacterales*	Carbapenem-	Blood	181	91	2,370	12,977,061	0.007	0.000 (0.000, 0.000)
	resistant	LRT	203	190	5,641	13,924,473	0.014	0.000 (0.000, 0.015)
		Urine	241	168	12,596	14,367,796	0.012	0.000 (0.000, 0.009)
	Extended-spectrum	Blood	237	873	3,036	17,153,552	0.051	0.027 (0.000, 0.052)
	cephalosporin-	LRT	242	1,837	7,017	16,832,810	0.109	0.077 (0.031, 0.127)
	resistant	Urine	291	3,165	15,246	17,450,730	0.181	0.125 (0.057, 0.207)
	Fluoroquinolone-	Blood	274	907	3,130	18,631,133	0.049	0.024 (0.000, 0.046)
	resistant	LRT	289	1,255	7,098	18,577,764	0.068	0.043 (0.016, 0.085)
		Urine	343	4,167	16,410	19,147,673	0.218	0.165 (0.082, 0.260)

^{*}Enterobacterales defined as E. coli, Klebsiella pneumoniae, K. oxytoca, and Enterobacter isolates. Enterobacter isolates includes Enterobacter, Enterobacter aerogenes, Enterobacter amnigenus, Enterobacter asburiae, Enterobacter cancerogenus, Enterobacter cloacae, Enterobacter cloacae complex, Enterobacter cloacae subspecies dissolvens, Enterobacter hormaechei, Enterobacter intermedius, Enterobacter kobei, Enterobacter ludwigii.

Isolate summary for SRIR models

		Specimen	Number of facilities in analysis	Number of drug resistant	Number of tested	Total patient-	Pooled resistant isolate rate, per 1000	Resistant isolate rate per 1000 patient-days,
Pathogen	Drug-resistance	source	dataset	isolates	isolates	days	patient-days	Median (Q1, Q3)
Enterococcus	Vancomycin-resistant	Blood	232	478	1,405	17,949,216	0.027	0.011 (0.000, 0.027)
		LRT	115	45	321	10,135,289	0.004	0.000 (0.000, 0.008)
		Urine	317	1,425	6,183	19,480,228	0.073	0.035 (0.000, 0.085)
Pseudomonas	Fluoroquinolone-	Blood	184	114	718	15,553,181	0.007	0.000 (0.000, 0.013)
aeruginosa	resistant	LRT	296	1,307	5,640	19,080,975	0.068	0.041 (0.000, 0.082)
		Urine	294	535	3,092	19,022,668	0.028	0.017 (0.000, 0.043)
	Multidrug-resistant	Blood	191	96	783	16,286,620	0.006	0.000 (0.000, 0.008)
		LRT	306	1,084	6,109	20,327,428	0.053	0.027 (0.000, 0.066)
		Urine	316	329	3,383	20,806,708	0.016	0.000 (0.000, 0.022)
Staphylococcus	Methicillin-resistant	Blood	285	971	2,330	19,364,507	0.050	0.040 (0.018, 0.067)
aureus		LRT	308	3,865	7,856	20,238,799	0.191	0.160 (0.085, 0.242)
		Urine	207	312	599	16,159,309	0.019	0.018 (0.000, 0.033)

Enterococcus includes Enterococcus faecalis, Enterococcus faecium, and Enterococcus

Isolate summary for pSIR models

Pathogen/Pathogen-Group	Specimen source	Number of facilities in analysis dataset	Number of isolates	Total patient- days	Pooled isolate rate, per 1000 patient-days	Resistant isolate rate per 1000 patient-days, Median (Q1, Q3)
Enterobacterales	Blood	352	3,557	22,026,801	0.161	0.169 (0.102, 0.223)
	LRT	353	8,399	21,694,825	0.387	0.257 (0.125, 0.430)
	Urine	389	19,035	22,073,214	0.862	0.723 (0.518, 1.007)
Enterococcus	Blood	352	1,527	22,026,801	0.069	0.034 (0.000, 0.066)
	LRT	353	399	21,694,825	0.018	0.000 (0.000, 0.016)
	Urine	389	6,854	22,073,214	0.311	0.229 (0.132, 0.373)
Staphylococcus aureus	Blood	352	2,524	22,026,801	0.115	0.093 (0.051, 0.140)
	LRT	353	8,161	21,694,825	0.376	0.271 (0.143, 0.415)
	Urine	389	633	22,073,214	0.029	0.016 (0.000, 0.037)
Pseudomonas aeruginosa	Blood	352	822	22,026,801	0.037	0.017 (0.000, 0.043)
	LRT	353	6,207	21,694,825	0.286	0.200 (0.104, 0.332)
	Urine	389	3,460	22,073,214	0.157	0.129 (0.052, 0.198)

Model details

High-level risk-adjustment summary

SRIR - Standardized Resistant Infection Ratio										
							Medical			Community-
		Specimen	Facility	Number	Number of	Percentage	school	Affiliation	Hospital	onset
Pathogen	Drug-resistance	source	type	of beds	ICU beds	of ICU beds	affiliation	type	length of stay	prevalence
Enterobacterales	Carbapenem-resistant	Blood								✓
		LRT							✓	✓
		Urine							✓	✓
	Extended-spectrum	Blood							✓	√
	cephalosporin-resistant	LRT		✓						✓
		Urine							✓	✓
	Fluoroquinolone-	Blood							✓	✓
	resistant	LRT		✓						✓
		Urine							✓	✓
Enterococcus	Vancomycin-resistant	Blood							✓	✓
		LRT*								
		Urine								✓
Pseudomonas	Fluoroquinolone-	Blood								✓
aeruginosa	resistant	LRT			✓					✓
		Urine								✓
	Multidrug-resistant	Blood				✓				
		LRT								✓
		Urine								✓
Staphylococcus	Methicillin-resistant	Blood			✓				✓	✓
aureus		LRT							✓	✓
		Urine				✓				✓

High-level risk-adjustment summary

	pSIR - pathogen-specific Standardized Infection Ratio										
Pathogen/Pathogen- Group	Specimen source	Facility type	Number of beds	Number of ICU beds	Percentage of ICU beds	Medical school affiliation	Affiliation type	Hospital length of stay	Community- onset prevalence		
Enterobacterales	Blood			✓				✓	n/a		
	LRT			✓					n/a		
	Urine	✓						✓	n/a		
Enterococcus	Blood		✓					✓	n/a		
	LRT							✓	n/a		
	Urine							✓	n/a		
Staphylococcus aureus	Blood			✓				✓	n/a		
	LRT			✓				✓	n/a		
	Urine							✓	n/a		
Pseudomonas	Blood			✓				✓	n/a		
aeruginosa	LRT			✓					n/a		
	Urine	✓						✓	n/a		

SRIR and pSIR reports in NHSN

SRIR and pSIR Reports

- We plan for SRIR and pSIR reports to be included in the NHSN application later this calendar year
- The release will add two new reports:
 - One with 21 SRIR tables
 - One with 12 pSIR tables
- Reports will default to facility-quarter level but will also be available at the half-year, year, and cumulative levels
- Once released, facilities that report eligible AR data will be able to generate SRIRs and pSIRs back to January 2019

Interpreting SRIR and pSIR values

- As ratios, SRIR and pSIR values are always greater than or equal to 0
- Similar to SIRs, lower values are considered better
- SRIR interpretations:
 - A value <1 indicates the rate of resistant HO infection was less than predicted
 - A value=1 indicates the rate of resistant HO infection was equal to predicted
 - A value >1 indicates the rate of resistant HO infection was greater than predicted
- pSIR interpretations:
 - A value <1 indicates the rate of HO infection was less than predicted
 - A value=1 indicates the rate of HO infection was equal to predicted
 - A value >1 indicates the rate of HO infection was greater than predicted

Example SRIR calculation

- Facility A reports 4 HO vancomycin-resistant Enterococcus (VRE) events in blood during Q1 of 2022
- 6 HO VRE events in blood are predicted for Facility A for Q1 of 2022
- Facility A's blood HO VRE SRIR for Q1 2022 would be calculated as:
 - SRIR = 4 observed/6 predicted = 0.667
- SRIR interpretation: Facility A's number of hospital-onset vancomycinresistant Enterococcus isolates from blood in Q1 of 2022 is 0.7 times what is predicted

Situations where a SRIR=0

- SRIR=0 indicates a facility reported the organism of interest from the specimen source of interest during the correct time period, but the organism was NOT resistant to the drug(s) specified
- For example, for HO VRE in blood, if a hospital reports 10 HO Enterococcus isolates from blood during the time of interest and all 10 are reported to be susceptible to vancomycin, the HO VRE blood SRIR would be 0 because there were 0 observed resistant infection events

Reasons a SRIR could be missing

- There were no specimens collected from the specimen source of interest during the time period of interest
- There were no organisms of interest isolated from the specimen source of interest during that time period
- The minimum precision criteria (for the number of predicted AR events)
 was not met
 - Minimum precision criteria: <0.3 predicted events

Example pSIR calculation

- Facility A reports 100 HO Staphylococcus aureus (SA) events in blood during 2022
- Facility A has 50 HO SA events in blood predicted for that year
- Their blood HO SA pSIR for 2022 would be calculated as:
 - pSIR = 100 observed/50 predicted = 2.000
- pSIR interpretation: Facility A's number of hospital-onset Staphylococcus aureus isolates in blood in 2022 is 2 times what is predicted

pSIRs=0 and reasons a pSIR value could be missing

- Using the example of SA in blood, a pSIR=0 indicates a facility reported at least one blood specimen in 2022, but no SA was isolated
- Reasons a pSIR value could be missing:
 - There were no specimens collected from the specimen source of interest during the time period of interest
 - There were no HO isolates (any organisms) from the specimen source of interest during the time period of interest
 - The minimum precision criteria (for the number of predicted infections) was not met
 - Minimum precision criteria: <0.3 predicted events

Questions?

NHSN@cdc.gov

Thank you!

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

